Aurinia Pharmaceuticals Inc

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Aurinia Pharmaceuticals Inc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Headquarters city: Edmonton
Headquarters country: Canada
Fiscal year end: December
Ticker symbol: AUPH
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001600620
EIN: 98-1231763

Board of directors

Follow this board

Brinda Balakrishnan · Director
Since 2023
Craig A. Johnson · Director
Since 2024
Daniel Billen · Director
Since 2023
David R.w. Jayne · Director
Since 2023
George M. Milne Jr. · Director
Since 2023
Jeffrey Allen Bailey · Director
Since 2023
Jill Leversage · Director
Since 2023
Joseph P. Hagan · Director
Since 2023
Karen L. Smith · Director
Since 2023
Kathleen Goetz · Director
Since 2025
Kevin Tang · Director · Chief Executive Officer
Since 2024
Peter Greenleaf · Director · Chief Executive Officer
Since 2023
R. Hector MacKay-Dunn · Director
Since 2023
Robert T. Foster · Director
Since 2023
Tina Susan Nova · Director
Since 2025

Chief executives

Peter Greenleaf · Chief Executive Officer

Dates unknown

Kevin Tang · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of May 15, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

6 of this board's directors also sit on 12 other boards. 7 are in the same sector.

Shared director Other board Same sector

Altimmune Inc. Same sector
via Peter Greenleaf
Amylyx Pharmaceuticals Inc. Same sector
via George M. Milne Jr.
Azenta Inc.
via Tina Susan Nova
Context Therapeutics Inc. Same sector
via Karen L. Smith
Exagen Inc. Same sector
via Tina Susan Nova
Heron Therapeutics Inc. Same sector
via Craig A. Johnson
Pelthos Therapeutics Inc. Same sector
via Peter Greenleaf
Skye Bioscience Inc. Same sector
via Karen L. Smith
abrdn Healthcare Investors
via Kathleen Goetz
abrdn Healthcare Opportunities Fund
via Kathleen Goetz
abrdn Life Sciences Investors
via Kathleen Goetz
abrdn World Healthcare Fund
via Kathleen Goetz

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $25,144,033; 11 purchases by 1 insider
Sold, last 12 months: $546,373; 2 sales by 1 insider

Date	Insider	Transaction	Shares	Price	Value
Sep 10, 2026	Robertson Stephen P. Officer (Chief Legal Officer)	Open-market sale	−11,939	$15.95	$190,427
Aug 21, 2026	Robertson Stephen P. Officer (Chief Legal Officer)	Open-market sale	−20,975	$16.97	$355,946
Jun 2, 2026	Kevin Tang Director, Officer (Chief Executive Officer), 10% owner	Open-market purchase	+206,005	$15.28	$3,147,756
Jun 1, 2026	Kevin Tang Director, Officer (Chief Executive Officer), 10% owner	Open-market purchase	+343,521	$15.28	$5,249,001
Jun 1, 2026	Kevin Tang Director, Officer (Chief Executive Officer), 10% owner	Open-market purchase	+99	$15.34	$1,519
May 29, 2026	Kevin Tang Director, Officer (Chief Executive Officer), 10% owner	Open-market purchase	+2,299	$15.35	$35,290
May 29, 2026	Kevin Tang Director, Officer (Chief Executive Officer), 10% owner	Open-market purchase	+262,682	$15.31	$4,021,661
May 18, 2026	Robertson Stephen P. Officer (Chief Legal Officer)	Grant or award	+115,541	—	—
May 18, 2026	Hearne Michael S Officer (Chief Financial Officer)	Grant or award	+116,144	—	—
May 18, 2026	Cole Ryan Officer (Chief Operating Officer)	Grant or award	+116,144	—	—
Mar 6, 2026	Keenan Greg Officer (SVP, Chief Medical Officer)	Shares withheld for tax	−8,069	$14.32	$115,548
Mar 3, 2026	Kevin Tang Director	Open-market purchase	+184,208	$14.22	$2,619,438
Mar 2, 2026	Miller Joseph M Officer (Chief Financial Officer)	Shares withheld for tax	−37,511	$14.21	$533,031
Mar 2, 2026	Donley Matthew Maxwell Officer (Chief Operating Officer)	Shares withheld for tax	−40,761	$14.21	$579,214
Mar 2, 2026	Peter Greenleaf Director, Officer (Chief Executive Officer)	Shares withheld for tax	−100,890	$14.21	$1,433,647

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

AbCellera Biologics Inc. Nasdaq: ABCL · Vancouver, Canada Organization Alpha Cognition Inc. Nasdaq: ACOG · Grapevine, Canada Organization Arbutus Biopharma Corporation Nasdaq: ABUS · Warminster, Canada Organization Aurora Cannabis Inc. Nasdaq: ACB · Edmonton, Canada Organization

Questions about Aurinia Pharmaceuticals Inc

Who is the CEO of Aurinia Pharmaceuticals Inc?

Peter Greenleaf is Aurinia Pharmaceuticals Inc's Chief Executive Officer.

How many directors are on Aurinia Pharmaceuticals Inc's board?

Aurinia Pharmaceuticals Inc's board has 15 directors: Brinda Balakrishnan, Craig A. Johnson, Daniel Billen, David R.w. Jayne, George M. Milne Jr., Jeffrey Allen Bailey, Jill Leversage, Joseph P. Hagan, Karen L. Smith, Kathleen Goetz and 5 others.

Are Aurinia Pharmaceuticals Inc insiders buying or selling shares?

Over the last 12 months, Aurinia Pharmaceuticals Inc insiders bought $25.1 million of shares in 11 purchases and sold $546,373 of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Aurinia Pharmaceuticals Inc connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="aurinia-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.